These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17506043)

  • 1. The construction of a functional photoactivatable cancer targeting bispecific antibody conjugate.
    Thompson S; Fawcett MC; Self CH
    ChemMedChem; 2007 Aug; 2(8):1162-4. PubMed ID: 17506043
    [No Abstract]   [Full Text] [Related]  

  • 2. Bispecific T-cell engaging antibodies for cancer therapy.
    Baeuerle PA; Reinhardt C
    Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies for polyclonal T-cell engagement.
    Baeuerle PA; Kufer P; Lutterbüse R
    Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
    Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
    Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibody-conjugated cytostatic drugs. Uses of monoclonal antibodies for new strategies in tumor therapy].
    Renner C; Pfreundschuh M
    Fortschr Med; 1994 Oct; 112(29):399. PubMed ID: 8001887
    [No Abstract]   [Full Text] [Related]  

  • 10. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dual-specificity therapeutic antibodies].
    Winckler T
    Pharm Unserer Zeit; 2009; 38(5):395-6. PubMed ID: 19711313
    [No Abstract]   [Full Text] [Related]  

  • 12. Construction of multiform scFv antibodies using linker peptide.
    Wang S; Zheng C; Liu Y; Zheng H; Wang Z
    J Genet Genomics; 2008 May; 35(5):313-6. PubMed ID: 18499076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
    Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
    Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells.
    Ranft K; Thepen T; Fischer R; Barth S; Stöcker M
    Cancer Lett; 2009 Sep; 282(2):187-94. PubMed ID: 19345477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotechnology-2009 AAPS national conference. 21-24 June 2009, Seattle, WA, USA.
    Wu C
    IDrugs; 2009 Sep; 12(9):539-42. PubMed ID: 19697269
    [No Abstract]   [Full Text] [Related]  

  • 17. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.
    Stadler CR; Bähr-Mahmud H; Celik L; Hebich B; Roth AS; Roth RP; Karikó K; Türeci Ö; Sahin U
    Nat Med; 2017 Jul; 23(7):815-817. PubMed ID: 28604701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528.
    Asano R; Sone Y; Ikoma K; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
    Protein Eng Des Sel; 2008 Oct; 21(10):597-603. PubMed ID: 18621782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.